Table 2.
Clinical and demographic characteristics of the GENUS Consortium Sample Collection.
| Patients | Controls | Familial High Risk | Statistic | df | p | ||||
|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|||||||
| N | Mean ± SD (Range) | N | Mean ± SD (Range) | N | Mean ± SD (Range) | ||||
| Age (years) | 5,197 | 39.3±12.2 (13–82) | 4,877 | 39.2±15.8 (8–86) | 725 | 34.9±16.0 (10–85) | F = 31.2 | 2, 10796 | <1x10−10 |
| Education Level (years) | 4,697 | 12.3±2.6 (1–24) | 4,031 | 13.3±2.6 (4–26) | 721 | 13.1±3.2 (3–24) | F = 163.4 | 2, 9446 | <1x10−10 |
| Premorbid IQ | 3,145 | 97.1±15.5 (44–145) | 1,393 | 107.6±10.7 (62–145) | 83 | 105.1±16.0 (45–134) | F = 263.4 | 2, 4618 | <1x10−10 |
| Current IQ | 1,889 | 93.8±18.1 (47–155) | 2,779 | 113.4±14.9 (67–161) | 602 | 105.1±15.6 (58–152) | F = 817.8 | 2, 5267 | <1x10−10 |
| Illness Duration (years) | 4,165 | 15.1±11.6 (<1–58) | --- | --- | --- | --- | --- | --- | --- |
| Age at Onset (years) | 4,124 | 23.8±8.6 (1–71) | --- | --- | --- | --- | --- | --- | --- |
| Global Assessment of Functioning | 1,764 | 59.8±15.9 (11–100) | --- | --- | --- | --- | --- | --- | --- |
| PANSS Positive symptoms | 2,916 | 16.3±7.3 (7–47) | --- | --- | --- | --- | --- | --- | --- |
| PANSS Negative Symptoms | 2,912 | 16.7±7.1 (7–43) | --- | --- | --- | --- | --- | --- | --- |
| PANSS General Symptoms | 2,919 | 32.0±11.8 (0–93) | --- | --- | --- | --- | --- | --- | --- |
| SAPS Positive Symptoms | 1,533 | 7.9±12.3 (0–121) | --- | --- | --- | --- | --- | --- | --- |
| SANS Negative Symptoms | 983 | 23.6±20.1 (0–103) | --- | --- | --- | --- | --- | --- | --- |
| Antipsychotic dose – current CPZEQ | 3,315 | 384.2±406.6 (0–5,000) | --- | --- | --- | --- | --- | --- | --- |
| Antipsychotic dose – lifetime average CPZEQ | 1,433 | 338.3±365.1 (0–3,125) | --- | --- | --- | --- | --- | --- | --- |
|
| |||||||||
| N | % | N | % | N | % | ||||
|
| |||||||||
| Sex (male/female; % male) | 3,417/1,781 | 65.7 | 2,419/2,458 | 49.6 | 317/408 | 43.7 | χ2 = 322.9 | 2 | <1x10−10 |
| Antipsychotic medication exposure | |||||||||
| Atypical | 2,100 | 49.1 | --- | --- | --- | --- | --- | --- | --- |
| Typical | 411 | 9.6 | --- | --- | --- | --- | --- | --- | --- |
| Both Typical and Atypical | 544 | 12.7 | --- | --- | --- | --- | --- | --- | --- |
| Naïve/None | 474 | 11.1 | --- | --- | --- | --- | --- | --- | --- |
| Unknown Class | 324 | 7.6 | --- | --- | --- | --- | --- | --- | --- |
| No information | 422 | 9.9 | --- | --- | --- | --- | --- | --- | --- |
| Diagnosis | |||||||||
| Schizophrenia | 3,973 | 76.4 | --- | --- | --- | --- | --- | --- | --- |
| Schizoaffective Disorder | 465 | 8.9 | --- | --- | --- | --- | --- | --- | --- |
| Schizophreniform Disorder | 93 | 1.8 | --- | --- | --- | --- | --- | --- | --- |
| Bipolar Psychosis | 338 | 6.5 | --- | --- | --- | --- | --- | --- | --- |
| Other Psychosis | 204 | 3.9 | --- | --- | --- | --- | --- | --- | --- |
| Psychosis Unknown Type | 126 | 2.4 | --- | --- | --- | --- | --- | --- | --- |
| Ancestral Population | χ2 = 567.6 | 12 | <1x10−10 | ||||||
| European | 3,686 | 71.2 | 3,396 | 69.7 | 632 | 87.2 | --- | --- | --- |
| East Asian | 697 | 13.5 | 1,117 | 22.9 | 3 | 0.4 | --- | --- | --- |
| African | 510 | 9.9 | 152 | 3.1 | 57 | 7.9 | --- | --- | --- |
| American (Predominantly Latino) | 140 | 2.7 | 30 | 0.6 | 3 | 0.4 | --- | --- | --- |
| South Asian | 50 | 1.0 | 35 | 0.7 | 7 | 1.0 | --- | --- | --- |
| Mixed | 28 | 0.5 | 11 | 0.2 | 10 | 1.4 | --- | --- | --- |
| No information | 68 | 1.3 | 135 | 2.8 | 13 | 1.8 | |||
| Handedness (right/other; % right-handed) | 2,322/260 | 89.9 | 2,378/252 | 90.4 | 609/59 | 91.2 | χ2 = 1.0 | 2 | 0.60 |
Data in this table are based on the total GENUS sample collection; data for the subset with genotype data are provided in Supplementary Table 2.
CPZEQ = chlorpromazine 100 mg equivalent; df = degrees of freedom; PANSS = Positive and Negative Syndrome Scale; SANS = Scale for the Assessment of Negative Symptoms; SAPS = Scale for the Assessment of Positive Symptoms; SD = Standard Deviation